Unattributed Code Systems

• http://id.who.int/icd10
• http://www.whocc.no/atc
• https://www.kemri.go.ke/fhir/CodeSystem/oncology-medication-category
• https://www.kenyacode.com/fhir/CodeSystem/kenya-cancer-staging
• https://www.kenyacode.com/fhir/CodeSystem/kenya-county-codes
• https://www.kenyacode.com/fhir/CodeSystem/kenya-oncology-cadres
• https://www.kenyacode.com/fhir/CodeSystem/kenya-oncology-qualification-codes
• https://www.kenyacode.com/fhir/CodeSystem/kenya-oncology-roles
• https://www.kenyacode.com/fhir/CodeSystem/kenya-oncology-service-areas
• https://www.kenyacode.com/fhir/CodeSystem/kenya-oncology-specialties
• https://www.kenyacode.com/fhir/CodeSystem/oncology-diagnostic-types
• https://www.sha.go.ke/fhir/CodeSystem/referral-source
• https://www.sha.go.ke/fhir/CodeSystem/referral-type

Copyright Fragment

This fragment is not visible to the reader

Copyright and Registered Trademark Uses

• IG © 2025+ Medby_Tech. Package medby#0.1.0 based on FHIR 4.0.1. Generated 2025-06-24 Links: Table of Contents | QA Report ( src )
• hl7.fhir.us.hai: Healthcare Associated Infection Implementation Guide ®© HL7 | CC0 ( src )
• A Condition profile for structured oncology diagnosis documentation in Kenya, aligned with national cancer registry reporting and HL7® FHIR® standards. ( src )
• Build Info: Local CI using HL7® FHIR® Build Tools ( src )
• Customized patient profile for oncology care in Kenya. This profile is part of the Oncology Implementation Guide for Kenya (Oncology-IG-Kenya) — a draft version (0.1.0) dated 2025-06-18. It models key patient elements aligned with Kenya’s national cancer registry, SHA (Smart Health Authority), DHIS2, and local care workflows. This guide demonstrates how HL7® FHIR® can be applied to transform cancer care, from screening to palliative support. It is a proof-of-concept created independently by a Kenyan digital health enthusiast, with no official endorsement, to inspire innovation using open health standards and locally relevant data modeling. ( src )
• Kenya faces a growing cancer crisis. This FHIR Implementation Guide (IG) is designed to model a comprehensive, standards-based oncology care pathway. It reflects the realities of Kenya’s healthcare system while showcasing how HL7® FHIR® can be adapted to support every stage of oncology—from prevention and early detection, through diagnosis and treatment, to survivorship and palliative care. ( src )
• The table below outlines how core stages of oncology care map to HL7® FHIR® resources: ( src )
• There are examples where a medication request may include the option of an oral dose or an Intravenous or Intramuscular dose. For example, "Ondansetron 8mg orally or IV twice a day as needed for nausea" or "Compazine® (prochlorperazine) 5-10mg PO or 25mg PR bid prn nausea or vomiting". In these cases, two medication requests would be created that could be grouped together. The decision on which dose and route of administration to use is based on the patient's condition at the time the dose is needed. ( src )
• This Implementation Guide demonstrates how HL7® FHIR® can be leveraged to enhance oncology care in Kenya. It includes standardized profiles such as OncologyKenyaPatient and OncologyObservationKenya, tailored search parameters, and extensions reflecting Kenya’s SHA and health system realities. ( src )
• This Implementation Guide is a demonstration of how HL7® FHIR® can be leveraged to enhance the quality, continuity, and coordination of oncology care in Kenya. It is developed independently by a Kenyan health tech enthusiast, with a passion for improving cancer outcomes through open standards and interoperable digital solutions. ( src )
• oncologyfhirigkenya - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions ( src )

External References